← back to search

Kristina Kligys

AbbVie (United States) · US
Area of research
Genetics · Immunology
Research interest
Research interests include Inflammatory Bowel Disease, Immunodeficiency and Autoimmune Disorders, Eosinophilic Esophagitis, and Microscopic Colitis.
h-index
14
citations
1,618
works
99
NIH funding
primary concept
Medicine
email

Recent publications

Extended Risankizumab Treatment in Patients With Crohn’s Disease Who Did Not Achieve Clinical Response to Induction Treatment
Clinical Gastroenterology and Hepatology 2025cited by 5position: middledoi
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies
Journal of Crohn s and Colitis 2024cited by 4position: middledoi
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial
Journal of Crohn s and Colitis 2023cited by 14position: middledoi
S1 Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial
The American Journal of Gastroenterology 2023cited by 12position: middledoi
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
The Lancet 2022cited by 375position: middledoi
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
The Lancet 2022cited by 307position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marc Ferrante · Universitair Ziekenhuis Leuven4 papers (2023–2025)Remo Panaccione · Nutrition-Génétique et Exposition aux Risques Environnementaux4 papers (2023–2025)Alexandra Song · AbbVie (United States)3 papers (2023–2025)Britta Siegmund · Nutrition-Génétique et Exposition aux Risques Environnementaux3 papers (2023–2025)Geert D’Haens · Vrije Universiteit Amsterdam3 papers (2023–2025)Peter M. Irving · Guy's and St Thomas' NHS Foundation Trust2 papers (2023–2023)Raja Atreya · University of Amsterdam2 papers (2023–2024)Tadakazu Hisamatsu · Nippon Kayaku (Japan)2 papers (2024–2025)Silvio Danese · Io Therapeutics (United States)2 papers (2023–2025)Brian G. Feagan · Western University2 papers (2023–2024)Jasmina Kalabic · AbbVie (Germany)2 papers (2023–2025)James O. Lindsay · Agricultural Research Service2 papers (2023–2025)Javier Zambrano · AbbVie (United States)2 papers (2024–2025)Yafei Zhang · North China University of Water Resources and Electric Power2 papers (2024–2025)Sofie Berg · Nutrition-Génétique et Exposition aux Risques Environnementaux2 papers (2023–2023)Ezequiel Neimark · Nutrition-Génétique et Exposition aux Risques Environnementaux2 papers (2023–2023)Kori Wallace · Nutrition-Génétique et Exposition aux Risques Environnementaux2 papers (2023–2023)Marla C. Dubinsky · Takeda (Japan)2 papers (2023–2025)Peter Bossuyt · Imelda Hospital2 papers (2023–2025)W. Rachel Duan · AbbVie (United States)2 papers (2023–2025)